Research programme: nanobubble therapeutics - ImaRxAlternative Names: MRX-804; MRX-820; MRX-850; NanO2
Latest Information Update: 04 Sep 2009
At a glance
- Originator ImaRx Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 07 Feb 2006 Preclinical trials in Stroke in USA (unspecified route)